Methsolon500 mg/vial

Methylprednisolone sodium succinate is an injectable corticosteroid used, when oral therapy is not feasible, for a wide range of severe or acute conditions, including:

• Severe allergic conditions unresponsive to conventional treatment (asthma, drug hypersensitivity reactions, angioedema, serum sickness, transfusion reactions)
• Endocrine disorders, including adrenocortical insufficiency (as an adjunct to primary therapy)
• Rheumatic and connective tissue disease flares (rheumatoid arthritis, systemic lupus erythematosus, acute gouty arthritis)
• Severe dermatologic conditions (pemphigus, severe erythema multiforme, exfoliative dermatitis)
• Gastrointestinal disease flares (ulcerative colitis, Crohn's disease)
• Respiratory disease (symptomatic sarcoidosis, aspiration pneumonitis, COPD exacerbations)
• Hematologic disorders (acquired haemolytic anaemia, idiopathic thrombocytopenic purpura)
• Cerebral edema associated with certain brain tumors
• Nervous system disease (acute exacerbations of multiple sclerosis)
• Short-term management of acute spinal cord injury, and as an adjunct in certain organ transplant and oncologic settings

Contains methylprednisolone sodium succinate for intravenous or intramuscular injection. Marketed products vary considerably in vial strength - commonly available as 40 mg, 125 mg, 500 mg, 1 g, and 2 g single-dose or Act-O-Vial presentations, with or without accompanying diluent. The generic name alone does not identify a single fixed strength; always confirm the exact vial strength on the specific product's own label, since dosing depends on the clinical situation rather than the vial size.

Methylprednisolone sodium succinate is an injectable corticosteroid used in hospital and clinical settings when oral corticosteroid therapy is not feasible or when a rapid, high-dose effect is needed. It is used across a wide range of severe allergic, inflammatory, autoimmune, and other conditions, and is given by intravenous or intramuscular injection or infusion. Marketed in several vial strengths, the appropriate dose depends entirely on the specific condition being treated rather than on a single fixed amount.

Therapeutic Class: Systemic Corticosteroid (Glucocorticoid)

Following intravenous administration, demonstrable anti-inflammatory effects are evident within one hour and persist for a variable period; excretion of the administered dose is nearly complete within 12 hours, so if constantly high blood levels are required, injections are generally given every 4 to 6 hours. It is also rapidly absorbed when given intramuscularly, with an excretion pattern similar to intravenous administration.

• May be given by intravenous injection, intravenous infusion, or intramuscular injection; intravenous injection is generally preferred for initial emergency use
• Rapid administration of large intravenous doses (greater than 0.5 g given over less than 10 minutes) has been associated with cardiac arrhythmias and cardiac arrest; high doses should be given over at least 30 minutes
• Injection into the deltoid muscle should be avoided due to a high incidence of subcutaneous tissue atrophy at that site
• For infusion, the reconstituted solution may be added to 5% dextrose in water, isotonic saline, or 5% dextrose in isotonic saline
• Use only the accompanying diluent or bacteriostatic water for injection with benzyl alcohol, as specified by the product; reconstituted solution should generally be used within 48 hours

The following should be assessed by a healthcare professional before combining with methylprednisolone:

• NSAIDs and aspirin, which increase the risk of gastrointestinal ulceration when combined with corticosteroids
• Live vaccines, which should generally be avoided during high-dose corticosteroid therapy due to immune suppression
• Anticoagulants such as warfarin, whose effect may be altered by corticosteroids, requiring closer monitoring
• Drugs affecting liver enzymes (such as phenytoin, rifampicin, or ketoconazole), which may alter methylprednisolone blood levels
• Potassium-depleting diuretics, which may increase the risk of low blood potassium when combined with corticosteroids

Common side effects

• Fluid retention and swelling
• Raised blood glucose
• Increased appetite
• Mood changes, insomnia, or restlessness
• Headache

Serious side effects (seek urgent medical attention)

• Signs of infection that may be masked by the corticosteroid's anti-inflammatory effect
• Cardiac arrhythmias or bradycardia, particularly with rapid administration of large doses
• Signs of a severe allergic (anaphylactoid) reaction: rash, swelling of the face or throat, difficulty breathing
• Dermal or subdermal skin depressions at the injection site
• Signs of gastrointestinal bleeding or perforation
• Psychiatric disturbances, including severe depression or psychosis, particularly at high doses
• Vision changes, which may indicate raised eye pressure or other eye complications with prolonged use

Pregnancy

Corticosteroids cross the placenta; use during pregnancy should only occur if the treating physician determines the benefit outweighs the potential risk, particularly with high-dose or prolonged therapy.

Breastfeeding

Corticosteroids are excreted in human milk; use during breastfeeding should be discussed with a healthcare professional, weighing the mother's need for treatment against potential infant exposure, particularly with high-dose or prolonged therapy.

• Cardiac effects: Rapid administration of large intravenous doses has been associated with cardiac arrhythmias and cardiac arrest; give high doses over at least 30 minutes.
• Infection risk: Corticosteroids may mask signs of infection and can increase susceptibility to new infections or reactivate latent infections, including tuberculosis; monitor closely, especially with prolonged use.
• Adrenal suppression: Prolonged use can suppress the body's own adrenal function; abrupt discontinuation after prolonged therapy should be avoided, and tapering is generally required.
• Injection-site skin changes: Avoid exceeding recommended doses and avoid deltoid muscle injection, due to risk of tissue atrophy.
• Avoid in cerebral malaria: Corticosteroids should be avoided in patients with cerebral malaria.
• Monitor for gastrointestinal, psychiatric, ophthalmic, and metabolic (including blood glucose) effects during treatment, particularly with high-dose or prolonged use.

Reports of acute toxicity or fatality following corticosteroid overdose are rare; overdose is unlikely to lead to a life-threatening situation in most cases, but repeated excessive dosing over time can cause or worsen effects such as fluid retention, raised blood glucose, and increased infection risk. If overdose is suspected, especially with very high or repeated dosing, contact a poison control center or seek medical care; treatment is generally supportive.

Store the unreconstituted product at controlled room temperature, protected from light, as directed on the product label. Once reconstituted, the solution should generally be used within 48 hours, or as specified by the manufacturer; discard any unused portion after this period.

• Elderly: May be more susceptible to some corticosteroid side effects, including osteoporosis, skin thinning, and glucose intolerance; use the lowest effective dose.
• Diabetes mellitus: Corticosteroids can raise blood glucose; monitor closely and adjust diabetes treatment as needed.
• Hepatic or renal impairment: Use with caution; dose adjustment may be needed based on clinical response.

High-dose corticosteroid therapy is generally continued only until the patient's condition has stabilized, usually not beyond 48-72 hours, before transitioning to a longer-acting injectable or oral preparation. For other indications, duration is individualized by the treating physician based on the specific condition and response to treatment; therapy should not be stopped abruptly after prolonged use.

The lyophilized powder must be reconstituted with the accompanying diluent or with bacteriostatic water for injection (with benzyl alcohol), following the specific product's instructions for volume and resulting concentration. Multiple-dose vials containing benzyl alcohol should not be used in neonates. Reconstituted solution should generally be used within 48 hours of mixing; discard any unused portion after this period.

Drug Class: Synthetic glucocorticoid (methylprednisolone ester)

Methylprednisolone works by binding to glucocorticoid receptors, which suppress the immune and inflammatory response - reducing swelling, redness, and immune cell activity involved in allergic, autoimmune, and inflammatory conditions. It also has effects on carbohydrate, protein, and fat metabolism, and on the body's stress response.

Methylprednisolone sodium succinate is used in pediatric patients for the same broad range of indications as in adults, with dosing individualized by weight and clinical condition by the treating physician. Growth and development should be monitored closely in infants and children on prolonged corticosteroid therapy.